University Gastroenterology

Running trials

• Recruiting

  NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

  NCT07683325· Phase 2· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Source

• Recruiting

  A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  NCT06581328· Phase 4· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Source

• Active, not recruiting

  A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  NCT06095128· Phase 4· Source

• Active, not recruiting

  A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  NCT06045754· Phase 4· Source

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease6 recruiting
• Obesity2 recruiting
• Ulcerative colitis2 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Source